BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hikma Pharmaceuticals Trading Update


2/14/2014 8:34:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

London, 14 February 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, will announce its full year results to 31 December 2013 on 12 March 2014. In advance of this, the company is providing an update to the market on the strong performance of its Injectables and Generics businesses towards the end of 2013.

Since issuing our Interim Management Statement on 8 November 2013, the Injectables and Generics businesses continued to perform very well and, as a result, Group revenue growth for the full year in 2013 will now be around 23%, ahead of our previous guidance of around 20%.

Injectables

Our global Injectables business has performed very well, with revenue growth of around 14%. Profitability has improved and we now expect an adjusted operating margin of around 30%. This reflects a particularly strong performance in the US, where we are focusing on higher value products, improved pricing, new product launches and tight cost control. We are confident that our Injectables business will continue to deliver strong revenue growth and an adjusted operating margin above 30% in 2014.

Generics

Our Generics business has benefited from strong doxycycline sales and we now expect Generics revenue of around $270 million for the full year. Looking ahead, we expect Generics revenue to be lower in 2014 due to increased competition in the US doxycycline market.

Branded

Our Branded business has performed in line with expectations, with revenue growth of around 5% for the full year, or 8% in constant currency. We continue to expect adjusted operating margin of around 24%, up more than 50 basis points from last year, as a result of our strategic decision to cut low margin tender sales, a focus on higher value products and greater emphasis on operational efficiencies.

We will provide our regular detailed guidance in respect of 2014, both for the business segments and the Group overall, when we announce our 2013 Preliminary Results on 12 March 2014.

Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/ +44 7776 477050
Lucinda Henderson, Investor Relations Manager +44 (0)20 7399 2765/ +44 7818 060211
FTI Consulting
Ben Atwell/ Julia Phillips/ Matthew Cole +44 (0)20 7831 3113
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES